Unraveling the Mystery: How Different Ligands Activate GPCRs with Varying Strengths
Unveiling the secrets of GPCR activation, scientists have discovered a fascinating correlation between ligand speed and the potency of their effects.
In a groundbreaking study published in Nature, researchers from St. Jude Children's Research Hospital have shed light on a long-standing puzzle in drug development. The key lies in understanding how different ligands, despite binding to the same G-protein coupled receptor (GPCR), can lead to varying levels of activation.
But here's where it gets controversial...
GPCRs, crucial proteins that transmit signals inside cells, are triggered by ligands, which are essentially chemical messengers. These signals are then transmitted through the activation of G proteins, resulting in various physiological effects. GPCRs are prime targets for drug development, with a third of FDA-approved drugs targeting these receptors. However, the lack of understanding about ligand variation has been a roadblock.
The study focused on the mu-opioid receptor, a well-known GPCR targeted by pain management drugs like morphine and codeine. Researchers found that the speed at which different ligands, or agonists, push this receptor through its activation steps determines how they affect it differently.
Imagine a kinetic trap...
A kinetic trap is like a hurdle that a GPCR faces during activation. It's a state where the receptor gets stuck in an intermediate shape, and it takes significant energy to move past it. Just like a small ball getting slowed down by a divot on a hill, while a larger ball rolls smoothly down without any hindrance.
Most GPCRs start signaling by changing their shape, activating and releasing a bound G-protein. These shape changes must overcome kinetic traps, and the study reveals that different agonists can push the GPCR through these traps, but at varying speeds.
And this is the part most people miss...
The varying rates of these processes explain the differences in efficacy, even though the end state remains structurally identical. Regardless of the strength of the agonist, the steps remain the same, but weaker agonists take longer to move through these steps, correlating with their reduced efficacy.
Capturing 'molecular movies' of drug action...
Researchers were able to capture 'molecular movies' of how three different drugs for the mu-opioid receptor fine-tune their signaling at G-proteins. This insight could be a game-changer in developing better pain relievers to combat the opioid epidemic and improve GPCR drugs in general.
The underlying source of variation...
By obtaining structures of intermediate states during GPCR-G protein activation, researchers compared partial, full, and super agonists of the mu-opioid receptor. They used cryo-electron microscopy (cryoEM) to capture images of G-protein activation release over time. Partial agonists were found to get the GPCR stuck for longer in a kinetic trap, while super and full agonists pushed through quickly.
Single-molecule imaging measurements further supported this mechanism, showing that full and super agonists gave the GPCR more dynamism, allowing it to overcome energy barriers between shape changes quickly. Partial agonists, on the other hand, led to a more rigid structure, struggling to overcome these barriers and getting stuck in a kinetic trap near the end.
Different agonists, different 'pushers'...
Skiniotis compares different agonists to different people pushing a sticky dimmer switch. All are moving it from off to on, but those of higher strength push faster, while lower-strength agonists get slowed or trapped along the way. This understanding can help us better comprehend GPCR function and guide the engineering of safer, more effective next-generation drugs.
A collaborative effort...
The study was a collaborative effort involving researchers from St. Jude, Stanford University, Baylor College of Medicine, and Washington University School of Medicine. It was funded by grants from various organizations, including the St. Jude Children's Research Hospital Collaborative Research Consortium on G protein-coupled receptors, the National Institutes of Health, and the American Lebanese Syrian Associated Charities (ALSAC).
St. Jude Children's Research Hospital is dedicated to advancing cures and prevention for childhood catastrophic diseases, with a global reach and innovative science at its core.
